Vaccine, DTP


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IM Booster immunisation against diphtheria, tetanus and pertussis 0.5 mL via deep IM inj into the deltoid muscle of the upper arm, at least 5 years after last dose. Prophylaxis of tetanus in wound management In cases of uncertain or <3 doses of primary immunisation: 0.5 mL via deep IM inj into the deltoid muscle of the upper arm. In cases of ≥3 doses of primary immunisation: Administer 0.5 mL if ≥10 years since last dose for minor wounds or if ≥5 years since last dose for tetanus-prone wounds (e.g. contaminated with dirt, soil or faeces). Refer to literature as dosage may vary with brand and local guidelines.
Dosage Details
Intramuscular
Prophylaxis of tetanus in wound management
Adult: In cases of uncertain or <3 doses of primary immunisation: 0.5 mL via deep IM inj into the deltoid muscle of the upper arm. In cases of ≥3 doses of primary immunisation: Administer 0.5 mL if ≥10 years since last dose for minor wounds or if ≥5 years since last dose for tetanus-prone wounds (e.g. contaminated with dirt, soil or faeces). Refer to literature as dosage may vary with brand and local guidelines.
Child: ≥10 years Same as adult dosage.

Intramuscular
Booster immunisation against diphtheria, tetanus and pertussis
Adult: 0.5 mL via deep IM inj into the deltoid muscle of the upper arm, at least 5 years after last dose. Refer to literature as dosage may vary with brand and local guidelines.
Child: ≥10 years Same as adult dosage.

Intramuscular
Active immunisation against diphtheria, tetanus and pertussis
Child: ≥6 weeks to <7 years As primary immunisation: 1st-3rd doses: 0.5 mL at 2, 4 and 6 months of age at 4-8 weeks interval; 4th dose: 0.5 mL at approx 15-20 months of age, at least 6 months after 3rd dose; 5th dose: 0.5 mL at 4-6 years of age. Doses given via deep inj into the anterolateral muscles of the thigh (≥6 weeks to <12 months of age) or the deltoid muscles of the upper arm (≥12 months to <7 years of age). Refer to literature as dosage may vary with brand and local guidelines.
Contraindications
Hypersensitivity. History of encephalopathy within 7 days with pertussis vaccine, progressive neurologic disorder (e.g. infantile spasms, uncontrolled or progressive epilepsy).
Special Precautions
Patient with history of Arthus-type hypersensitivity or Guillain-Barre syndrome with tetanus vaccine, bleeding disorders (e.g. thrombocytopenia), hypotonic-hyporesponsive episode or crying for ≥3 hours within 48 hours or seizures within 3 days with pertussis vaccine altered immunosuppression. Children (with personal or family history of seizures). Pregnancy and lactation. Postpone immunisation in patients with acute infection or severe febrile illness.
Adverse Reactions
Significant: Syncope, Guillain-Barre syndrome, brachial neuritis; apnoea (premature infants).
Gastrointestinal disorders: Nausea, vomiting, diarrhea, abdominal pain.
General disorders and administration site conditions: Asthenia, fatigue, malaise, fever, chills, inj site reactions (e.g. pain, oedema, erythema).
Metabolism and nutrition disorders: Anorexia.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia.
Nervous system disorders: Headache, dizziness, somnolence.
Psychiatric disorders: Irritability.
Skin and subcutaneous tissue disorders: Rashes.
Potentially Fatal: Hypersensitivity or anaphylaxis reaction.
MonitoringParameters
Monitor for anaphylaxis and signs of syncope for 15 minutes after inj.
Drug Interactions
Decrease effect with immunosuppressive agents (e.g. corticosteroids, antimetabolites).
Action
Description: DTP vaccine, a combination of diphtheria and tetanus toxoids and acellular pertussis adsorbed vaccines, promotes immunity against diphtheria, tetanus and pertussis by inducing specific antibody production.
Storage
Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance with local requirements.
ATC Classification
J07AJ52 - pertussis, purified antigen, combinations with toxoids ; Belongs to the class of pertussis bacterial vaccines.
J07AJ51 - pertussis, inactivated, whole cell, combinations with toxoids ; Belongs to the class of pertussis bacterial vaccines.
References
Adacel TDAP Injection, Suspension (Sanofi Pasteur, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 18/07/2018.

Adacel, Suspension for Injection (Sanofi Pasteur Europe). MHRA. https://products.mhra.gov.uk/. Accessed 18/07/2018.

Anon. Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 18/07/2018.

Anon. Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 18/07/2018.

Boostrix Suspension (GlaxoSmithKline Biologicals SA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 18/07/2018.

Boostrix Suspension for Injection in Pre-filled Syringe (GlaxoSmithKline UK). MHRA. https://products.mhra.gov.uk/. Accessed 18/07/2018.

Buckingham R (ed). Diphtheria, Tetanus, and Pertussis Vaccines. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/07/2018.

Daptacel Injection, Suspension (Sanofi Pasteur, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 18/07/2018.

Infanrix Suspension (GlaxoSmithKline Biologicals SA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 18/07/2018.

Disclaimer: This information is independently developed by MIMS based on Vaccine, DTP from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in